Genetic redundancy poses a major problem to the analysis of gene function. RNA interference allows the downregulation of several genes simultaneously, offering the possibility to overcome genetic redundancy, something not easily achieved with traditional genetic approaches. Previously we have used a polycistronic miR155-based framework to knockdown expression of three genes of the early B cell factor family in cultured cells. Here we develop the system further by generating transgenic mice expressing the RNAi construct in vivo in an inducible manner. Expression of the transgene from the strong CAG promoter is compatible with a normal function of the basal miRNA/ RNAi machinery, and the miR155 framework readily allows inducible expression from the Rosa26 locus as shown by Gfp. However, expression of the transgene in hematopoietic cells does not lead to changes in B cell development and neuronal expression does not affect cerebellar architecture as predicted from genetic deletion studies. Protein as well as mRNA levels generated from Ebf genes in hetero-and homozygous animals are comparable to wild-type levels. A likely explanation for the discrepancy in the effectiveness of the RNAi construct between cultured cells and transgenic animals lies in the efficiency of the sequences used, possibly together with the complexity of the transgene. Since new approaches allow to overcome efficiency problems of RNAi sequences, the data lay the foundation for future work on the simultaneous knockdown of several genes in vivo.
Introduction
One of the surprising findings of gene targeting in mice are knock-out animals with no obvious phenotype. While a proportion of these cases is likely due to incomplete phenotypic testing or a manifestation only under certain non-standard conditions, it is estimated that 10 -15% of knock-out mice do not have an obvious phenotype [1] . The vast majority of such cases is thought to derive from functional redundancy between duplicated and highly homologous genes [2] . In favour of this hypothesis, duplicate genes occur in all organisms, especially in multicellular eukaryotes with approximately 50% of mouse genes having a related member in the genome [3] [4] [5] . While these facts have interesting and sometimes hard to reconcile implications for evolutionary biology [6, 7] , gene duplications and redundancy often mask the true contribution of single genes, making it difficult to discern the function of each copy by knocking out individual genes [8] .
Interestingly, conserved gene duplicates in vertebrates are specifically enriched for signal transduction and developmental function [9] . Good examples of this are the MRF family of transcription factors, acting as master regulators of vertebrate skeletal muscle development, and the Hox gene cluster [10] . Another interesting case is the early B cell factor (Ebf) family of transcription factors. All four members show a high level of sequence conservation, reaching 80 -90% at the nucleotide level within conserved domains, and all four members bind to the same DNA sequence [11, 12] . Despite a strong expression in tissues like the olfactory epithelium and in many neuronal cells, deletion of Ebf1 results in a distinct phenotype, i.e. the complete block of early B cell development [13] . This finding was unexpected, but Ebf1 is the only family member expressed in hematopoietic cells, whereas the tissues mentioned above express other Ebf genes in a largely overlapping manner [14] [15] [16] [17] . In fact, in addition to B cells, Ebf1 is the only Ebf gene expressed in the embryonic striatum and in cranial nerve nuclei, and Ebf1-deficient mice display atrophy and abnormal cellular migration, axonal fasciculation and projection [18] [19] [20] . Ebf2 and Ebf3 are also expressed in a largely overlapping pattern, and deletion of the single genes leads to a mixture of distinct and overlapping phenotypes causing lethality at the age of approximately two months or immediately after birth respectively. Ebf2 null mice display abnormalities in the cerebellum and peripheral nerve [21, 22] . Mice double heterozygous for Ebf2 and Ebf3 recapitulate common defects, such as defective projection of olfactory neurons, but do not display some of the defects occurring only in single knock-outs, arguing that the function of Ebf genes is dose-dependent and at least partially redundant [23] .
In an effort to overcome functional redundancy and examine the contribution of Ebf factors in general to the support of hematopoietic stem cells, we employed the SIBR (synthetic inhibitory BIC-derived RNA) vectors, a new approach to downregulate several genes simultaneously based on RNA interference [24] . In this system shRNA sequences are embedded into the framework of miR155/BIC including the flanking sequences, which are cleaved by the RNAseIII enzyme Drosha. This allows the concatemerisation of several shRNAs, and the inclusion of a marker gene, in our case Gfp. Furthermore, regulated expression of the RNAi construct is possible since it uses RNA polymerase II-driven promoters. Overall, this results a flexible system to express several shRNAs together with a marker gene in a single polycistronic mRNA driven by PolII [25] . We were able to successfully downregulate Ebf1, Ebf2 and Ebf3 and to demonstrate redundancy between these genes in retrovirally infected cultures of osteoblastic cells [24] . The same vector has been used also by other groups to inhibit the Ebf proteins in a variety of different cells [26, 27] . As this system proved useful in cell culture approaches in different contexts, we wanted to develop it further and overcome the limitations of in vitro approaches and retroviral infections. Here, we report the generation of transgenic mice with a targeted insertion of the SIBR-based EbfRNAi construct into the murine Rosa26 locus, and describe the effects of its induced expression.
Results

Generation of EbfmiRNA transgenic mice
The successful down-regulation of Ebf1, Ebf2 and Ebf3 using one miRNA construct allowed us to analyse the biological effects of this highly conserved protein family in cell culture [24] . While this approach opens new possibilities in studying biological roles independent of redundancy, it remains limited to in vitro assays and the expression of the miRNA construct via transfection or viral infection. To overcome these limitations we wanted to develop this system further and use it in vivo by generating mice with a targeted insertion. We had previously generated two different miRNA constructs, RNAi-a and RNAi-b, targeting the mRNAs of Ebf1, Ebf2 and Ebf3 at different positions, primarily to control for off-target effects of the miRNA generated [24, 28] . The single shRNAs bind to regions of the Ebf mRNAs corresponding to the DNA binding or the adjacent IPT/TIG-domain (of unknown function) of the encoded proteins ( Figure S1A ) and are concatemerised as indicated ( Figure  S1B ). Therefore, as two different constructs were available, we wanted to analyse the effectiveness of the RNAi constructs in detail before going in vivo. Therefore, HEK293T cells were transfected with expression plasmids for flag-tagged Ebf1, Ebf2 and Ebf3. In parallel, all six single constructs (two per Ebf gene), double and triple constructs were co-transfected. Coexpression of the single RNAi constructs resulted in the downregulation of the respective Ebf protein, but left the other family members relatively unaffected, indicating specificity but also a high level of effectiveness. The double RNAi constructs against Ebf2 and Ebf3 led to their strong down-regulation, but left Ebf1 relatively unchanged, demonstrating that neither specificity nor effectiveness are compromised by the concatemerisation via the flanking region of miR155. Finally, expression of the triple RNAi constructs induced a loss of Ebf proteins to almost undetectable levels ( Figure S2 ). Although the single RNAi constructs seemed to show slight differences in downregulation efficiencies, these were minor and could be due to experimental variances. In fact, no differences were observed with the double and triple constructs, confirming data from the down-regulation of endogenous Ebf proteins [24] . Therefore, we decided to use both constructs for the generation of targeted mouse ES cells.
Since miRNAs are standard class II mRNAs driven by RNA polymerase II [29] , yet depend on strong expression, we decided to target the insertion to the Rosa26 locus. However, instead of relying on the endogenous transcriptional activity of the locus we decided to use the synthetic CAG (CMV early enhancer/ chicken β-actin) promoter, which has very strong transcriptional activity [30, 31] . In combination with a transcriptional Stop site and a PGK::Neo resistance cassette, both flanked by loxP sites, immediately downstream of the CAG promoter ( Figure 1A ), this construct allows strong and tissue-specific expression of the insert [32] . The insert, which follows immediately after the loxP sites consists of the Gfp gene and the short hairpin sequences concatemerised by the flanking region of miR155 ( Figure 1A ). This sequence was cut from the pcDNA6.2-GW/EmGFP vector that was described before [24] , and is also analysed here ( Figure S2 ).
The targeting construct was used for electroporation of IDG3.2 murine ES cells, which were selected by G418. 600 resistant ES cell clones were picked and analysed for correct integration of the construct by Southern blot. In case of the external 5' probe, the appearance of a 6kb band in an EcoRI digestion and of a 12 kB band with a ScaI digestion indicates the correct integration of the construct. Figure 1B shows two clones with integration of the RNAi-A (A-xx) and two clones with integration of the B construct (B-xx). Hybridising Southern Blot to the internal Gfp probe results in the predicted bands of 3 kb for the EcoRI digest and 12 kb for the ScaI digest, confirming the correct and unique integration of the targeting vector ( Figure 1C ). In addition to the Southern Blot, all positive clones were also confirmed by sequencing. Overall, a 7.5% targeting efficiency was achieved over 600 clones tested, confirming the high recombination efficiency published for this locus [33, 34] .
No leakiness and high inducibility of the transgene in murine ES cells
To test the transgene functionally before going in vivo, we transfected ES cell clones with the pGK-cre-bpA plasmid (kind gift of Dr. Kurt Fellenberg, Institute of Genetics, University of Cologne), which leads to the expression of the Crerecombinase in transfected cells. In consequence, the transcriptional Stop sequence should be deleted and the transgene including the Gfp gene should come under control of the CAG promoter (Figure 2A ). ES cells were harvested 48h post-transfection and analysed by flow cytometry for the expression of Gfp. Figure 2B indicates that cells transfected with the mock vector do not express Gfp, and a low percentage of cells shows apoptosis as detected by propidium iodide. Transfection of the Cre-encoding plasmid however, leads to an expression of Gfp in approximately 30% of cells, again with a low percentage of cells showing apoptosis ( Figure 2B ). This indicates that the construct is not leaky, i.e. there is no expression of the transgene in presence of the Stop sequence, and that the transgene is efficiently induced via Cre-mediated excision of the Stop cassette. Furthermore, expression of the transgene does not influence viability of the cells.
No leakiness, high inducibility and strong expression of the transgene in vivo
Since all tests in ES cells provided evidence for the correct insertion and the functioning of the transgene, we proceeded to generate transgenic mice by standard conditions. Two different ES cell clones for each RNAi construct were injected into blastocysts and chimeric mice were obtained with both transgenic constructs, RNAi-a and RNAi-b. However, germ-line transmission was only successful with chimeric mice transgenic for the RNAi-a construct. As RNAi-a and RNAi-b did not differ significantly in their ability to down-regulate Ebf proteins in vitro ( Figure S2 and [24] ), we continued to analyse these mice and will refer to them as Rosa26
RNAi . To determine leakiness, inducibility and functionality in vivo, we wanted to induce expression of the transgene in hematopoietic cells. Ebf1 is expressed in early B cells and is necessary for the transition from fraction A to fraction B during B cell development [13] . Furthermore, miRNAs and the protein machinery required for their processing are important for the development of other hematopoietic cells like T and B cells [35] . Thereby, the functionality of the transgene can be tested in early B cells and potentially unspecific or off-target effects by examining T cell development, making the hematopoietic system ideal to study both aspects. To this end, we crossed the Rosa26
RNAi mouse line to the vav Cre line, which is active in hematopoietic stem cells and their derivatives [36] . In a first analysis, we wanted to determine the inducibility and the level of expression of the transgene, as these are two critical parameters for the effectiveness of RNAi. Single cell suspension from the bone marrow of adult mice from various genotypes was analysed by flow cytometry for the expression of Gfp. In all control mice, wt::wt, wt::Rosa26
RNAi/+ and vav Cre ::wt, no expression of Gfp and a percentage of approximately 50% B220-positive cells could be detected, indicating again no leakiness of the construct. A small reduction in the number of B220-positive cells was observed in the presence of the recombinase, but this phenotype did not reach statistical significance, therefore it might represent a slight tendency, but does not proof phenotypic changes due to the expression of the Cre recombinase. The vast majority of bone marrow from vav Cre ::Rosa26 RNAi/+ is shifted into the Gfp positive channel, with virtually all B220-positive cells also expressing Gfp. The level of expression of Gfp varies between several different populations, but ranges between one to three shifts in logarithmic units above wild-type, with the majority of cells at around two log-shifts ( Figure 3A ). Bone marrow cells from vav
RNAi/RNAi show exactly the same pattern of Gfp-positive cells when plotted against B220, but the expression of Gfp is shifted to even higher levels, with very few cells remaining negative for Gfp ( Figure 3A ). Statistical analysis shows that the described differences in the expression of Gfp are highly significant, and also indicate that the number of B220-positive cells is reduced from 53 RNAi/RNAi mice, indicating a potential but weak influence of the transgene on B cell development ( Figure 3B ).
No alterations in early B cell fractions mediated by expression of the transgene
As we detected a high expression of the transgene, particularly in B cells and a slight reduction of B220-positive cells, we continued to analyse the functionality of the RNAi transgene. Since Ebf1 is the only Ebf family member expressed in haematopoietic cells and is required for the progression from fraction A to fraction B in early B cell development [13] , we expected a block or at least a downregulation of cells in the transition from fraction A to fraction B, depending on the efficiency of the construct. Single cell suspensions from mice of the indicated genotypes were stained for B220 and CD43, and double positive cells, which comprise fractions A -C were analysed. No differences in the percentage of these cells were detected ( Figure S3 ). For further analysis, these cells were gated and analysed for expression of BP-1 and CD24, allowing the individual fractions to be distinguished. Again, no differences beyond standard 
Expression of the transgene does not interfere with Ebf1 levels in vivo
As no differences in early B cell fractions could be detected in hematopoietic cells, yet the cells express the transgene, we wanted to determine the levels of Ebf1 under these conditions. Therefore, we sorted fractions A, B and C according to the sorting gates indicated in Figure 5 A from mice carrying the same genotypes as before. Analysis of these early B cell Figure 5C ). Quantification of the protein amount by densitometry confirmed this observation by showing that no significant differences in Ebf protein levels exist based on the various genotypes ( Figure 5D ). Therefore we conclude that although the transgene mediates down-regulation of Ebf proteins in cell culture, and it is expressed at high levels in B cells from transgenic mice, its expression does not affect Ebf1 protein levels in vivo.
No alteration in cerebellar cyto-architecture in the Ebf2
GFPiCre ::Rosa26
RNAi line
Previous studies have clearly indicated that targeted deletion of one member of the Ebf gene family (Ebf2) impairs cerebellar development. In particular, cerebellar Purkinje cells (PCs) are decreased in number affecting the size and lobulation of the null cerebellum. One PC subpopulation is selectively reduced, and PC migration into the cerebellar cortex is impaired or delayed [21, 37] . Ebf2 exerts an autocrine/paracrine control over PC survival by activating Igf1 gene expression [27] . In light of these previous findings, we tested the combined effect of Ebf1-3 down-regulation on cerebellar development. This analysis was conducted on the adult (P60) progeny of an Ebf2
Cre x Rosa26 RNAi/+ cross. Ebf2-Cre is activated at the outset of PC development, and robust Cre levels are detected in the cerebellar primordium as early as E11.5 [26] . This transgene marks the PC lineage, as shown by genetic fate mapping (A.B., unpublished observations). Our results clearly indicate that Ebf2
Cre ::miRNA +/-mice feature no major cerebellar defects ( Figure 6A-D) . DAPI staining indicated that cerebellar lobulation is unaffected by RNAi activation in PC progenitors. Moreover, transgenic PCs express normal levels of Calbindin (CaBP), a Ca 2+ binding protein whose levels decrease rapidly upon PC degeneration. Finally, RNAi-expressing PCs exhibit a normally branched dendritic tree. Thus, no obvious abnormalities were scored in RNAi-expressing cerebella.
Expression of Gfp and the miRNA-transgene are correlated but do not influence Ebf protein levels
The data indicate a clear discrepancy between the functionality of the construct in vitro and in vivo. One possible explanation is an insufficient expression level of the transgene. So far we have analysed Gfp-positive cells as one bulk population, but as shown in Figure 3A , the expression of Gfp shows a broad spectrum, from high to low expression in largely three distinct populations. This offers the possibility to analyse these populations individually, to examine if expression-related effects are masked in the bulk analysis. To this end, we isolated low, middle and high Gfp-expressing cells in addition to Gfp , reflecting the presence of two instead of one allele of the transgene ( Figure 7A ).
The expression of the transgene in these sorted populations was analysed in qPCR by primers spanning from the 3'-end of Gfp to the last inserted miRNA sequence. As shown in Figure  7B , Gfp-negative cells from all examined genotypes displayed no detectable expression of the transgene, while cells from gates 2 -4 show increasing expression of the transgene (Figure 7B ), revealing a correlation in the expression of the transgene with Gfp. Therefore, if expression plays a role, we might be able to see an influence on Ebf1 protein levels in the most highly expression populations. However, western blot analysis of cells sorted according to the gates showed that Ebf1 was present in the different fractions at comparable levels ( Figure 7C ), indicating that too low expression of the transgene alone does not explain the observed inefficiency in vivo.
Discussion
RNAi has evolved as a means to down-regulate the expression of single target genes in vivo [38] . Initially, shorthairpin RNAs were driven by RNA polymerase III-dependent promotors to affect the expression of a single target gene [39] [40] [41] [42] [43] [44] . Tissue-specificity can be achieved via the disruption of the promotor by a neomycin-resistance cassette flanked by loxP sites [45] [46] [47] . However, neither does this system allow to incorporate a marker gene, nor to choose the activating potential of the promotor. When it was found that oversaturation of the cellular shRNA/miRNA pathway was sufficient to cause morphologic changes and even fatality in mice, it became clear that a regulated expression was important in vivo [48] . At the same time, shRNA sequences were discovered that are embedded in more complex RNAi transcripts, which are driven by RNA polymerase II, opening the possibility of tissuespecific expression and inclusion of a marker gene [29, 49, 50] . Among those, miRNA30 was first shown to mediate inhibition of cognate mRNAs with natural as well as designed miRNA sequences [51] . This system was developed further, and now allows the down-regulation of target RNAs in a tissue-specific and, by adding a doxycycline-inducible promoter, reversible manner [52] [53] [54] .
In some situations however, as to overcome genetic redundancy or to inhibit more than one signalling pathway, it is desirable to inhibit several genes concomitantly. The miR155 precursor is embedded within the third exon of the non-coding BIC gene, and the miR155 precursor together with flanking regions is sufficient to confer the oncogenic activities of BIC/ miR155 [55, 56] . Based on this, a polycistronic expression vector for RNA polymerase II was developed, in which the flanking regions, which are subject to cleavage by the RNAse Drosha, are used to concatemerise sequences encoding shRNAs [25] . At least two different synthetic shRNAs can be expressed from a single transcript and coupling to a marker gene like Gfp is possible without compromising the efficiency of the system. We used this framework to incorporate sequences directed against Ebf1, Ebf2 and Ebf3 and observed a strong down-regulation upon ectopic expression but also of the endogenous genes, allowing us to establish a redundant role of these proteins in the support of hematopoietic stem cells [24] . As these constructs also worked in various other cellular contexts [26, 27] , we wanted to extend the system and to overcome the limitations of cell culture and retroviral infections.
The most striking finding of our experiments is that an RNAi construct that mediates down-regulation of cognate RNA very efficiently in cell culture does not have a biological effect in vivo. Several possibilities with different likelihoods can explain this discrepancy. One of our major concerns was the level of expression necessary to achieve a down-regulation in vivo. Originally, one of the reasons for choosing RNA polymerase III for the expression of shRNAs was the high level of expression that can be achieved. Therefore, we did not want to rely on the expression mediated by the endogenous Rosa26 locus, which ranges from low to mid level, depending on cell type, but is not near typical RNA polymerase III or viral promotor driven expression [57, 58] . Therefore, we chose the synthetic CAG promotor, which is among the strongest inducers of eukaryotic expression known [31] . We do observe a good inducibility of Gfp in ES cells and particularly in hematopoietic cells after vav Cre mediated activation of the transgene. In this case, the expression results in a shift of three log units in flow cytometry, and can be further enhanced to a shift over four logarithmic units by crossing the transgene to homozygosity. This expression is very likely to be higher than the levels achieved using the tet-transactivator to down-regulate p53 [52] . Therefore, and as Ebf genes are not expressed at very high levels (own unpublished data), we consider it very unlikely that too low expression of the transgene is the reason for the lack of down-regulation of Ebf proteins. The expression of the transgene at different levels allowed us to study a potential influence on Ebf protein levels closer. The analysis of cells expressing GFP not at all, or at low, middle or high levels shows that the transgene encoding is detectable at corresponding levels, which is not surprising, given that both are encoded by one mRNA. This also shows that the transgene encoding for the miRNA sequences is really present in the transgene. However, no changes in Ebf protein level can be detected, not even in the highest expressing cells, ruling out that a potential effect is masked in the bulk analysis of Gfppositive cells and showing that the observed expression levels alone do not explain the lack of down-regulation. Furthermore, a higher expression of the transgene in homozygous transgenic animals, but no down-regulation of Ebf proteins in these mice argues against a dose-dependent effect.In addition, we conclude that expression of the transgene from the CAG promotor does not saturate the miRNA/shRNA machinery, as miRNAs control many aspects of the development of hematopoietic cells, but we do not observe any phenotypic changes [35] . A second possibility might be problems with the processing of a complex polycistronic mRNA in vivo. To generate the knock-in mice, we used exactly the same DNA construct as in the retroviral vector used for the infection of cultured murine and human cells. Therefore, since cells of the same species were used, differences in the processing machinery between cultures cells and transgenic mice seem rather unlikely. Additionally many studies show that the basic RNAi machinery is ubiquitously expressed. The second possibility is that the basic machinery is the same in vitro and in vivo, but the artificial RNAi construct generated poses more problems in its correct processing than endogenous miRNAs. Chaining of more than three shRNA sequences strongly decreases the efficiency in mediating down-regulation for each shRNA and the expression of Gfp is attenuated by shRNA chaining, presumably due to increased processing (data not shown). Together, this might indicate that the construct is on the border of loosing its effectiveness due to its complexity. Again, the expression of Gfp in vitro and in vivo and the down-regulation of Ebf proteins in cultured cells argues against this possibility, although we consider it more likely than the two afore mentioned possibilities.
A third general possibility is the design and efficiency of the RNAi sequences used to inhibit the Ebf proteins. The precise sequence requirements for efficient RNAi are not well understood [59] , although it is known that thermodynamic asymmetry, low G/C content and a strong bias for A/U at the 5' end of the guide strand are important [60] [61] [62] . We have tested the RNAi sequences for down-regulation in cultured cells by transfection of the shRNA encoding plasmid and by retroviral infection of primary cells for efficient down-regulation of transfected and endogenous Ebf proteins [24] . In both cases however, the RNAi transcripts result from a multitude to several origins of expression (plasmids / retroviral integration sites), but not from a single genomic locus as is the case in the transgenic mice. In fact it is this aspect where the biggest differences between the in vitro and in vivo approach occur. Based on a large scale approach, it has been estimated that only 3% of all possible RNAi sequences for a particular gene elicit efficient knockdown at the level of single copies [28] . Of all the possible explanations mentioned here, we consider problems with the design and the efficiency of the RNAi sequences as single genomic copies most likely to explain the discrepancy between in vitro and in vivo, i. e. the absence of a detectable downregulation of Ebf proteins.
In summary, we have used a new miR155-based system to explore the potential to knockdown the expression of several genes simultaneously. This approach was successfully in vitro, however, its direct translation in vivo did not result in the expected down-regulation. We think that the most likely explanation for this discrepancy lies in the efficiency of the RNAi sequences as single genomic copies. This, together with the complexity of the whole RNAi transcript, consisting of three short hairpins and Gfp, likely results in an overall efficiency that is too low to detect and that potentially can be compensated for. We do not think that the overall expression or differences in the endogenous basic miRNA/RNAi machinery are likely explanations. The data presented here clearly show that expression of the transgene from the CAG promoter is compatible with a normal function of the basal miRNA/RNAi machinery in hematopoietic cells, and the miR155 framework works well in the context of inducible expression from the Rosa26 locus as shown by Gfp. The data presented here provide the foundation for future work on the simultaneous knockdown of several genes in vivo, as the problems concerning the efficiency of the RNAi sequences can be overcome [59] .
Experimental Procedures Generation of transgenic mice
Two different sequences to inhibit Ebf1, Ebf2 and Ebf3 (RNAi-a and RNAi-b) were excised together with EmGFP from the pcDNA6.2-GW/EmGFP vector (Invitrogen, [24] ), and inserted into the XbaI site of the pRTS targeting vector (kindly provided by D. Calado, Immune Disease Institute Inc., Boston, MA). Mouse ES cells derived from C57Bl/6 x 129S6/SvEvTac-F1 strains (IDG3.2) were electroporated with this construct and colonies were isolated in the presence of 170 µg/ml G418 (Gibco). DNA extraction and Southern Blots were performed as described [63] . The correct insertion of the targeting sequences was analysed using an external 550 bp 5' probe and an internal Gfp probe of 723 bp. The 5' probe was cut from the pRosa26-5-pBS KS plasmid using EcoRI and PacI, the Gfp probe was isolated from the pcDNA6.2-GW/EmGFP vector using DraI. Hybridisation was carried out for 16 hours at 65°C in Church buffer (0.4 M Na 2 HPO 4 ), membranes were washed 3 x 10 min at 58°C in wash buffer (0.2 x SSC, 0.5% SDS) and bands were detected using a phospoimager (Fuji Bas 1000). Two correctly targeted clones representing RNA-a and RNA-b constructs were injected into C57BL/6 blastocysts that were implanted into pseudopregnant females. Chimeric mice were bred to obtain germ-line transmission. Two male chimera (80%) corresponding to the RNA-a clone were selected to get heterozygous mice. Mutant mice were backcrossed with C57Bl/6 wild-type mice for more than 6 generations. All experiments involving animals were designed in agreement with the stipulations of the San Raffaele Institutional Animal Care and Use Committee, the Helmholtz Zentrum München and the Regierung von Oberbayern. The protocol and all experiments involving animals was approved by the ethics committees of the afore mentioned institutions. All efforts were made to minimise animal suffering.
Genotyping
For genotyping of mice tails were digested for at least 
Cell-culture, Transfections, Plasmids
HEK293T cells were kept under standard conditions in DMEM medium (+ 10% FCS, 1% Pen/Str/Glu; Gibco), and transfected using polyethylenimine (Gibco) according to standard protocols. For ectopic expression Ebf1, Ebf2 and Ebf3 were cloned into the pcDNA3.1 vector (Invitrogen) in frame with an N-terminal Flag-tag (Sigma).
Flow cytometry, Antibodies
For flow cytometry single cell suspensions were prepared by trypsinising ES cells or by aspirating bone marrow according to standard procedures. Isolated cells were blocked for unspecific binding using CD16/32 and incubated with either biotinylated or directly fluorochrome-conjugated antibodies. Cells were measured or sorted using either an LSRFortessa or a FACSAriaIII (BD Biosciences) and data were analysed using FACSDiva (Becton Dickinson GmbH) and FlowJo 9.3 (Treestar Inc.) software. For depletion of dead cells propidium iodide was used. Antibodies directed against the following markers were obtained from BD Biosciences: B220 (RA3-6B2) and CD43 (RM4-5), BP-1 (6C3), CD24 (30-F1), CD16/32 (=FcγRII/III; 2.4G2).
Isolation of RNA and Quantitative RT-PCR
mRNA was isolated using peqGOLD TriFast TM (Peqlab) according to manufacturer's instructions, cDNA was synthesised using SuperScript II reverse transcriptase (Invitrogen) and the oligo-dT primer (Roche). qPCR reactions were performed in duplicate with SYBR Green I Master in a LightCycler® 480II (Roche) with standard conditions: 95 °C for 10 min followed by 45 cycles of 95 °C for 10 s, 65 °C for 10 s and 72 °C for 10 s. Primer sequences: Hprt fwd 5´-tgc tgg tga aaa gga cct ctc g-3´, rev 5´-tct ggg gac gca gca act ga-3´; β-Actin fwd 5'-tgt ggt ggt gaa gct gta gc-3', rev 5'-gac gac atg gag aag atc tgg-3'; Ebf1 fwd 5´-ggg gac agt gca gat ggt aa-3´, rev 5 -caa ctc act cca gac cag ca-3´; Gfp fwd 5'-acc tac ggc gtg cag tgc ttc agc-3', rev 5'-gtc ctc gat gtt gtg gcg gat ctt g-3'; miRNAfwd: 5'-ggc atg gac gag ctg tac aa-3', miRNA-rev3: ctc tag atc aac cac ttt gt-3'. Three independent measurements were performed for each qPCR analysis, error bars represent the standard deviation of the mean. The comparative CT method was used to calculate the expression levels of RNA transcripts, and the quantified individual RNA expression levels were normalised for the respective β-actin expression levels, unless stated otherwise. Since we measured the relative RNA expression levels, the indicated expression levels were set as 1 or 100.
Histological procedures
Postnatal mice were anaesthetised with Avertin (Sigma, St Louis, MO, USA) and perfused with 0.9% NaCl followed by 4% paraformaldehyde (PFA). Tissues were fixed with 4% PFA, cryoprotected in 30% sucrose overnight, embedded in OCT (Bioptica), sectioned on a cryotome (18 μm). Cryosections were immunostained with the following antibodies: rabbit or mouse anti-calbindin (1:1000, Swant, Bellinzona, Switzerland); rabbit anti-GFP (1:700; Invitrogen); chicken anti-GFP (1:500; Abcam, Cambridge, UK).
Statistics
P-values were determined with the Student's two-tailed t-test for independent samples, assuming equal variances on all experimental datasets.
Immunoblotting, Antibodies
Protein isolation and immunoblotting was carried out according to standard procedures, antibodies used were α-panEbf [24] , α-β-Actin (AC-74, Sigma), α-Flag (M2, Sigma), The secondary α-mouse-IgG . HRP antibodies were obtained from Sigma, the secondary α-rat-IgG + IgM . HRP antibody was purchased from Jackson Immuno Research. Bands in western blot experiments were quantified using the open source software ImageJ (http://rsb.info.nih.gov/ij/; W. S. Rasband, NIH, National Institutes of Health, Bethesda, MD). 
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